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                              INTRODUCTION:
Chronic pancreatitis is a condition characterised by irreversible  destruction and 
fibrosis  of  the  exocrine  parenchyma,  leading to  exocrine  pancreatic  insufficiency  and 
progressive  endocrine failure  leading  to  diabetes.  Alcoholic  chronic  pancreatitis  is  the 
commonest type of chronic pancreatitis seen in the western  world, while in the tropics there is 
a distinct non-alcoholic type of chronic pancreatitis of uncertain aetiology, which is  far more 
common. Several names have been proposed for this type  of chronic pancreatitis including 
tropical  chronic  pancreatitis (TCP),  tropical  calcific  pancreatitis,  juvenile  pancreatitis 
syndrome, Afro-Asian pancreatitis, and fibrocalculous pancreatic  diabetes. 
TCP  can  be  defined  as  a  juvenile  form  of  chronic  calcific  non-alcoholic 
pancreatitis  prevalent  almost  exclusively in  the developing  countries of  the tropical  world. 
Some of its distinctive features are younger age at onset, presence of large intraductal calculi, 
an accelerated course of the disease leading the end points  of diabetes and/or steatorrhoea, 
and a high susceptibility to pancreatic cancer. 
Kini reported the first case of pancreatic calculi from India in 1937 and this was 
followed by reports of  pancreatic calculi  observed at postmortem from Vellore in southern 
India. However, it was after Geevarghese, one of  the pioneers in the field, documented one of 
the  largest  series in  the  world  from  Kerala  state  in  Southern  India  that  TCP  attracted 
international attention.
                 SPINK 1(Serine  protease inhibitor, Kazal type 1) is a potent protease inhibitor and 
is considered to be a major protective mechanism in preventing inappropriate  activation of 
pancreatic enzyme cascade by inhibiting up to 20% of trypsin activity.1 Since the inhibitory 
molecule provides the first line of defence against premature activation of trypsinogen  inside 
the  pancreas,  it  has  recently  attracted  a  lot  of  attention  as  a  possible  cause  of  chronic 
pancreatitis.  Recently  an  association of  hereditary  pancreatitis  has  been  shown  with  the 
SPINK 1 gene.1 The association between  SPINK gene and TCP has now been reported by a 
number of groups 2-6.Since all the above studies on TCP and others on other forms of chronic 
pancreatitis have shown a strong association with this gene,7 it is likely that this could be at 
least one of the genes predisposing to chronic pancreatitis in general and TCP in particular. 
Surgeons frequently find pancreatic head mass when operating. The obvious 
difficulty  is  to  make  the  correct  preoperative  differential  diagnosis  between  chronic 
pancreatitis and pancreatic tumor. The first step is to reach a diagnosis, with some certainty,  
prior to the operation. The second step in the case of a tumor is the accurate staging and 
deciding whether or not it is resectable. On the one hand, time and cost must be considered; 
on  the  other  hand,  the  therapy  must  be  decided.  Obtaining  information  about  the 
characteristics of the pancreatic disease (nature, size, exact location) and establishing the 
tissue diagnosis preoperatively may simplify the decision to operate and the operation itself.
In the case of chronic pancreatitis, the aim of the operation is to eliminate pain 
and other symptoms, while in the case of cancer; the purpose is to remove the malignant  
tissue.  In  most  patients,  it  is  possible  to  identify  the  disease  on  the  basis  of  previous 
examinations together with preoperative diagnostic techniques such as exploration, palpation 
and fine-needle aspiration biopsy.
Chronic pancreatic head mass should be operated upon with Beger’s or Frey’s 
procedure while pancreatic head tumors should be treated by means of head resection with  
the aim of preserving the pylorus or the Whipple procedure may be used. When the diagnosis 
is in doubt, a radical approach is thought to be best.
Differential Diagnosis
Frequently both chronic pancreatitis and pancreatic carcinoma may present with 
the same symptoms. In either condition, most patients are thin, and even emaciated, and may 
appear  to  have malignant  disease,  which should always be considered in  the  differential 
diagnosis.  A  variety  of  non-invasive  and  invasive  diagnostic  methods  are  available  to 
differentiate pancreatic cancer from chronic pancreatitis, and, used in combination, they can 
accomplish these goals with considerable accuracy. Despite remarkable technical advances 
in diagnostic procedures within the last decade, there is more potential for misclassification of 
adenocarcinoma of the pancreas, than for any other type of cancer because of the difficulty of 
an accurate diagnosis. Major differential diagnoses are proximal duct dilation or pancreatic  
carcinoma that has developed from pre-existing chronic pancreatitis. The definitive diagnosis 
can be difficult or impossible, even when the pancreas   is exposed at surgery. Direct biopsies 
are  about  60% sensitive  for  malignancy.  This  difficulty  is  compounded  by  the  facts  that 
patients  with  chronic  pancreatitis  are  at  increased  risk  of  developing  pancreatic  ductal  
adenocarcinoma and patients with pancreatic ductal adenocarcinoma often have focal areas 
of  chronic  pancreatitis.1 Hence,  the  two  key issues  in  the  evaluation  of  focal  pancreatic 
masses in the setting of chronic pancreatitis are the ability to differentiate between carcinoma 
and  chronic  pancreatitis  mimicking  carcinoma  and  the  impact  of  this  differentiation  on 
subsequent  surgical  triage  and  management.  So  many  patients  with  carcinoma  of  the 
pancreas die because their disease is not detected until late in its course. Methods that can 
detect pancreatic neoplasms earlier, while still resectable, improve patient outcome.
Pancreatic Head Mass
There is a subgroup of these patients with pancreatic head mass, in whom the 
complexity of differential diagnosis is enhanced. The majority of pancreatic tumors (70%) are 
localized to the pancreatic head and chronic pancreatitis seems to prefer the head region as 
well thus causing pancreatic head mass. The largest portion of resectable pancreatic tumors 
is present in the pancreatic head. This expression is widespread in clinical practice but not so 
extensively present in the literature. It  reflects a disparity involving two different diseases, 
chronic pancreatitis and carcinoma of the pancreas, with specific diagnostic and therapeutical 
aspects.
 Chronic  pancreatitis  has  been  suggested  as  a  risk  factor  for  pancreatic 
carcinoma, and can mimic pancreatic carcinoma as well. In a larger series of patients who 
underwent resection for chronic pancreatitis, cancers were found in 4/64 cases8 and 4/250 
cases, 9 but the number of patients who underwent pancreatic head resection due to false 
positive tumor diagnosis is not known.
The  management  and  prognosis  in  the  case  of  chronic  pancreatitis  or 
carcinoma  of  mass  in  the  pancreatic  head  region  is  different.  The  diagnosis  is  still  
problematic. 
The aim of diagnostic efforts in the case of "head mass" is:
• To choose conservative therapeutic measures 
• To determine interventional and surgical treatment 
• To avoid the misdiagnosis either chronic pancreatitis or pancreatic cancer. 
                            
                                      REVIEW OF LITERATURE
Evidence that chronic pancreatitis increases the risk of pancreatic cancer 
The association between chronic pancreatitis and cancer has been confirmed in 
a number of epidemiological studies. During the 1980s, two small case-control studies noted 
an increased yet  insignificant  number  of  pancreatic  cancers  among patients  with  chronic 
pancreatitis  .10,  11 Between  1990  and  1993,  three  studies  noted  a  small  but  significant 
increased risk  of  pancreatic  cancer  in  patients  with  chronic  pancreatitis  .12,  13,  14 In  1993, 
Lowenfels  et  al  15 published  the  results  of  the  International  Pancreatitis  Study  Group's 
multicenter historical cohort study of 2015 subjects with chronic pancreatitis. These subjects 
were recruited from clinical  centers in six countries.  A total  of  56 cancers were identified 
among these patients during a mean follow-up of 7.4±6.2 years.  For subjects with a minimum 
of 5 years of follow-up, the standardized incidence ratio was 14.4. The cumulative risk of 
pancreatic cancer in subjects with chronic pancreatitis for 10 and 20 years was 1.8% and 
4.0%,  respectively.  Furthermore,  the  risk  of  pancreatic  cancer  was  independent  of  the 
underlying cause of chronic pancreatitis. Thus, the risk of pancreatic cancer in patients with 
chronic pancreatitis appeared to far exceed any other known risk factor, including cigarette 
smoking (relative risk from 8 studies varied from 1.2 to 3.1 .16  Subsequently, five additional 
studies  demonstrated  a  significant  risk  of  pancreatic  cancer  in  patients  with  chronic 
pancreatitis.17-21
Evidence that tropical pancreatitis increases the risk of pancreatic cancer 
The  link  between  TP  and  pancreatic  cancer  is  strong.   The  incidence  of  
pancreatic cancer among adult patients with TP is striking, however. For example, in 1992 
Augustine and Ramesh 22 reported 22 pancreatic cancers among 266 patients with TP over 
an 8-year period (8.3%). In this cohort, the risk was highest after age 40, and patients with TP 
often had features of dysplasia as well as cancer in resected pancreatic specimens. In 1994 
Chari et al 17 reported that over a 4.5-year period 24 of 185 patients with TP died, and that 6  
(25%) died of pancreatic cancer. The average age of onset was 45±7 years, and the relative 
risk compared with those without TP was 100. Other reports confirm these observations.23 
Thus, current evidence suggests that the risk of pancreatic cancer is very high in patients with 
long-standing TP.
Pathways to carcinogenesis
Development  of  pancreatic  cancer  in  any  individual  requires  a  progressive 
series of genetic events typically occurring within pancreatic duct cells.24, 25 The genetic events 
must alter a critical group of genes that have been broadly categorized as oncogenes, those  
that promote cell growth, and tumor suppressor genes that normally suppress cell growth and 
division. Mutations in the oncogene K-ras and in the tumor suppressor genes p53, p16, DPC4 
have  been  detected  in  a  majority  of  pancreatic  tumors  24.  As  the  number  of  mutations 
accumulates in the cells progressing toward adenocarcinoma, the morphology acquires the 
characteristics  of  more  aggressive  tumors.  However  the  exact  sequence  of  mutation 
development, if necessary and the complete repertoire of critical mutations have yet to be 
discovered.24-29 
Specific  genes  that  are  known  to  be  mutated  in  ductal  pancreatic 
adenocarcinoma can be divided into four groups based on the frequency with which they can  
be detected. The k-ras codon 12 and the p16 gene alterations are found in more than 90% of  
pancreatic cancers 30-33. These mutations appear to occur early as they are often detected in 
preneoplastic  lesions  and  may  be  found  in  patients  with  chronic  pancreatitis  34-37.  The 
frequency of k-ras mutation is approximately 90% in all ductal pancreatic adenocarcinomas, 
and nearly 100% in typical ductal adenocarcinoma cancer 31, 32. The p16 gene product is also 
frequently altered or lost through nucleotide deletions, mutations, and epigenetic alterations 
including methylation that alters gene expression38. The fact that the p16 and k-ras mutations 
occur early, and that they are in the overwhelming majority of tumors, suggests that these 
mutations are necessary but not sufficient for pancreatic cancer development.
A second group of genes in which mutations that occur in approximately 50% of 
those tumors examined include the p53 (50–75%) and DPC4 (55%)  39,  40.  The third group 
includes germline mutations, including those in the BRCA2 gene. Mutations in the BRCA2 
gene occur in 7–10% of pancreatic cancer tumors 41. A fourth group that includes a group of 
genes mutated in 5% or less of pancreatic tumors include the LKB1/STK11 and MKK4, the 
transforming growth factor-beta receptors I or II, and the retinoblastoma (RB1) genes.   42-
45Carcinogenesis in chronic pancreatitis
As the pathway from normal ductal epithelium to pancreatic cancer becomes 
clear,  we  can  begin  to  investigate  the  accelerated  pathway  from  chronic  pancreatitis  to 
pancreatic  cancer.  The  first  question  is  whether  cationic  trypsinogen  mutations  or  Cystic 
fibrosis transmembrane conductance regulator (CFTR) mutations represent key steps in the 
carcinogenesis pathway. The second question is whether chronic pancreatic inflammation per 
se promotes mutations and chromosomal deletions in known oncogenes.
At  least  two  studies  investigated  chronic  pancreatitis-associated  mutations  in  the 
trypsinogen  gene  or  CFTR gene  in  patients  with  apparently  sporadic  pancreatic  cancer.  
Hengsler  et  al46 analyzed genomic DNA for  R122H mutations in  the trypsinogen gene in 
pancreatic  cancer  samples from 34 patients and corresponding normal  tissue from 28 of  
these individuals. No mutations were found. These data suggest that underlying trypsinogen 
gene mutations are uncommon in sporadic pancreatic cancers, and that trypsinogen R122H 
mutations are unlikely to be an important step in carcinogenesis. Malats et al 47 investigated 
the  possibility  that  common  CFTR  mutations  were  a  risk  factor  for  sporadic  pancreatic  
cancers. The incidence of deltaF508 mutation and the 5T allele variant was similar to controls, 
however. Again, the presence of these pancreatic disease-associated mutations is unlikely to 
be an important step in pancreatic cancer development.  Although these two studies have 
limitations  in  size  and  scope,  they  suggest  that  pancreatitis-associated  genes  are  in 
themselves not important in sporadic carcinogenesis. The increased risk of pancreatic cancer 
is likely through a different mechanism.
Does  chronic  pancreatic  inflammation  per  se  facilitate  development  of  key 
mutations  or  loss  of  chromosomal  material?  Substantial  experimental  data  is  becoming 
available, especially with respect to K-ras mutations. These mutations are generally not seen 
in normal pancreatic tissue and were thought to be specific for pancreatic cancer. Numerous 
reports suggest, however, that K-ras mutations are also common in chronic pancreatitis. 48, 49 
Indeed, the K-ras in patients with chronic pancreatitis may be localized to areas of the duct 
with  hyperplasia  50,  suggesting  focal  progression  toward  carcinogenesis.  Ductal  dysplasia 
also appears to be increased in TP. Augustine and Ramesh22 observed dysplasia in two of five 
resected  specimens  in  patients  with  TP and  cancer,  whereas  no  dysplasia  was  seen  in 
sporadic  pancreatic  cancers.  Thus,  focal  areas  of  dysplasia,  possibly  harboring  K- ras 
mutations, frequently arise within the context of chronic pancreatitis. The mechanism remains 
to be determined, however.
                              Future risk reduction and preventative strategies will likely include  
chemoprevention 51 or vaccination 52. Researches in these areas are in their infancy, however, 
and no recommendations can yet be given.
DIABETES MELLITUS:
In  the  diagnosis  of  pancreatic  head  tumors,  diabetes  mellitus  has  received 
particular attention. This metabolic alteration is, in fact, associated with pancreatic cancer in 
more than 80% of cases, and in some it is characterized by reduced glucose tolerance and 
reduced insulin secretion53-56. There is a body of clinical and experimental data demonstrating 
that pancreatic-cancer-associated diabetes mellitus is due to the cancer itself. It has been 
suggested that soluble mediators released by pancreatic cancer cells play a role in interfering 
with the metabolism of glucose. Pancreatic-cancer-associated diabetes mellitus or glucose 
intolerance are improved, or cured, following surgical removal of the pancreatic mass57. This 
indicates that diabetes mellitus is not correlated with islet cell destruction, but to the presence 
of the tumor itself.  Furthermore, in pancreatic cancer patients,  the release of insulin after  
glucagon stimulation indicates a reduced beta cell function58. In agreement with this clinical 
data, the treatment of isolated islets of Langerhans with pancreatic cancer conditioned media 
dissociates insulin from amylin secretion59.  Moreover,  it  has been demonstrated in clinical 
series that besides the presence of an altered function of Langerhans islets, there is also a 
peripheral insulin resistance56,  57.  In this respect it  has been demonstrated that pancreatic 
tumor  extracts  determine  an  altered  glycogen  synthesis  in  isolated  rat  muscles60. 
Furthermore, pancreatic cancer conditioned media can also induce fasting hyperglycaemia in  
SCID mice61 as well as inhibiting hepatic glycolysis, thus possibly favouring the synthesis of 
tryglycerides  62,63.  It  has  been  suggested  that,  one  of  the  possible  pancreatic  cancer-
associated  diabetogenic  products,  soluble  low molecular  weight  peptides play a  role63.  A 
further  valuable  laboratory  tool  in  the  diagnosis  of  pancreatic  head  mass  might  be  the 
identification of this/these substances and their determination in serum or urine.
Evidence For the primary alteration of islet cells in pancreatic carcinogenesis:
 The incidence of 72% of cases with islet cell alteration in the study by saruc et al 
correlates  with  the  frequency  of  abnormal  glucose  metabolism  in  the  pancreatic  cancer 
patients131.  Remarkably,  most  altered islet  cells  were in  the vicinity of  the cancer.Another 
noteworthy finding was the sign of altered islet cell differentiation, including the formation of 
intrainsular ductular structures and the expression of tumor- associated antigens CA 19-9, 
TAG-72, and/or DU-PAN-2 in islet cells and in intrainsular ductular cells.This finding indicates 
that islet cells have the ability to form abnormal cell populations in these patients.
Differences in the clinical expression of pancreatic cancer:
               It is presently unclear why mosy pancreatic cancer patients (70-80%) develop 
Impaired glucose tolerance (IGT) or diabetes and the minority (20-30%) do not.Although IGT 
improves after surgery in many patients, in some it either does not or it gets worse.It is highly 
possible  that  either  the  altered  cells  producing  the  diabetogenic  substances  exist  in  the  
teletumoral area not removed by surgery or some hidden (metastatic) tumors are left behind,  
for example in the liver131.
Differences in diabetes induced by chronic pancreatitis and pancreatic cancer:
            Unlike the islets in pancreatic cancer patients, which are of normal size or enlarged, 
about 95% of the islets in primary chronic pancreatitis measure less than 100 micro meter in  
diameter.Diabetes improves after a 70% pancreatectomy in pancreatic cancer but not after 
resectional surgery in chronic pancreatitis.
         Thus the occurrence of diabetes in pancreatic cancer cannot be explained by a single  
mechanism.The increase in peripheral  insulin resistance, suppression of insulin secretion, 
impaired proinsulin conversion, altered fat and carbohydrate metabolism, presence of acute  
and chronic pancreatitis,  medications for underlying disease, altered nutritional habits and 
many other factors seem to play important roles in the development and course of pancreatic 
cancer.
JAUNDICE:
       The distal bile duct traverses the posterior aspect of the head of the pancreas 
before entering the duodenum in 60% to 80% of individuals. In the remainder, the duct lies in  
a groove between the pancreatic parenchyma and the duodenum. Therefore, several types of 
changes  involving  the  pancreas  may  affect  the  distal  CBD,  including  reversible  edema, 
pseudocyst formation, and progressive, irreversible pancreatic fibrosis and calcification.64 
Chronic pancreatitis accounts for 10% of all common bile duct (CBD) strictures. 
Such stenoses occur in up to 30% of all patients with chronic pancreatitis and up to 40% of  
patients undergoing ERCP with moderate to severe disease65 .The highest incidence of biliary 
obstruction occurred in chronic pancreatitis patients who had an inflammatory mass in the 
head  of  pancreas.  Izbicki  et  al  and  Beger  et  al  reported  a  60%  and  56%  incidence, 
respectively, in patients with chronic pancreatitis that predominantly involved the head of the 
gland and who underwent duodenum-preserving pancreas head resection. The majority of 
these strictures do not cause symptoms and are found incidentally at ERCP.66,  67 However, 
they also may cause persistent obstructive jaundice, chronic abdominal pain, abnormalities in 
biochemical  tests  of  liver  function,  recurrent  cholangitis,  secondary  biliary  cirrhosis,  and 
choledocholithiasis.68 Of the patients who present with symptoms, 70% will  have changes 
because of obstructive biliary disease as seen in a liver biopsy specimen. 
Petrozza et al have reported different shapes of stricture segments including the 
smooth  tapering  variety,  funnel  shape,  rat-tail,  bent-knee,  hourglass  and  complete 
obstruction. However, it has been reported that a particular radiologic configuration of CBD 
stricture is  not  helpful  in  predicting the nature of  underlying process.  Therefore it  is  very 
difficult  to  discount  pancreatic  cancer  on  the  basis  of  radiologic  findings,  particularly  in 
patients with tumor- forming pancreatitis.
Determining whether biliary obstruction is due to chronic pancreatitis or malignancy 
can be a very challenging clinical problem. This differentiation is of utmost importance since 
malignancy will  require  resection  whereas  a  biliary  drainage  procedure  would  suffice  for  
benign disease.
CT ABDOMEN:
Transabdominal ultrasonography of the pancreas is limited by different patient 
dependent restrictions (obesity, meteorism, etc.).  Nowadays, CT is the most important, and 
sometimes, the initial imaging modality of the pancreas.
We can elevate the tumor detection rate and reliable assessment of resectability 
with  the  use  special  examination  techniques  such  as  spiral  hydro-CT.  The  latter  is  a 
combination of pharmacological intestinal paralysis and water distension of the stomach and 
duodenum with  specific  reference to  the tumor detection rate,  differentiation of  malignant 
versus benign tumors and assessment of tumor resectability.
Pancreatic tumours
The main question in cases with pancreatic head mass is the verification or the 
exclusion of malignancy which is often difficult. 
A circumscribed mass is the primary, but not necessarily an early sign of ductal 
pancreatic adenocarcinoma. An increase in diameter and roughness of the contour of the 
pancreas  are  unreliable  signs  of  malignancy.  The  masses  contained  a  central  zone  of  
diminished attenuation in about 80% of the cases69. On unenhanced CT most tumors have 
the same density as normal pancreatic tissue and can easily be missed if the tumor is small 
and  the  contour  of  the  gland  is  not  deformed.  With  spiral  CT  and  bolus  contrast 
administration, the tumor-pancreas contrast is best seen during the early phase of pancreatic 
perfusion.  The  tumor  as  a  hypodense  lesion  can  be  distinguished  from  the  opacified 
pancreatic parenchyma. A cystic central portion can demonstrate necrosis or the hemorrhage 
in  the  tumor.  The  border  between  the  pancreas  and  the  retroperitoneal  space  and  the 
surrounding organs is often indistinct70.
The  pancreatic  duct  and/or  common  bile  dilatation  is  critically  indicative  of 
malignancy. After intravenous contrast enhancement, dilatation of the biliary tract becomes 
clearly visible and the contour of the pancreatic duct can be better evaluated 71, 72.
Reaction surrounding the tumor occasionally creates a fuzzy appearance of the 
tumor region mimicking pancreatitis. The high contrast of peripancreatic vessels on contrast-
enhanced CT allows assessment of vascular encasement.
The  secondary  signs,  such  as  enlarged  lymph  nodes,  regional  metastases, 
hepatic metastases, ascites confirm the diagnosis of malignancy.
In contrast to adenocarcinoma, the mass of anaplastic carcinoma show marked 
enhancement after contrast administration
Acinar  cell  carcinomas usually  present  as  well  demarcated  tumors  of  low 
attenuation and minor or no enhancement after contrast administration.
MRCP:
The most sensitive diagnostic modality in suspected biliopancreatic diseases is 
endoscopic retrograde cholangiopancreatography (ERCP). However, the success rate of the 
examination mainly depends on the experience of the endoscopist, and does not exceed 95-
98% even in the largest specialized centers. Previous operations (Billroth II, Roux-en-Y or  
biliary-enteric anatomy), duodenal stenosis, or duodenal diverticulum make cannulation of the 
ducts  difficult  or  even  impossible,  and  increase  the  risk  of  complications.  If  ERCP fails,  
intravenous  (i.v)  or  percutaneous  transhepatic  cholangiography  (PTC)  is  the  alternative 
method. Since the diagnostic accuracy of i.v cholangiography is very low, it is no longer used.  
PTC is  invasive,  may be associated  with  severe  complications,  and can successfully  be 
applied if the intrahepatic biliary tree is dilated. PTC and i.v cholangiography are both unable  
to visualize the pancreatic  duct.  There is clearly a  need for a noninvasive,  sensitive and 
specific diagnostic modality for patients with suspected biliopancreatic disease if ERCP fails.  
Magnetic  resonance  cholangiopancreatography  (MRCP)  is  a  new  noninvasive  diagnostic 
modality capable of producing high-quality images of the pancreatobiliary tree. It has been 
emphasized  that  its  sensitivity  (81-100%),  specificity  (94-98%),  positive  (86-93%)  and 
negative (94-98%) predictive values and diagnostic accuracy (94-97%) are as high as those 
of  ERCP,  which  makes MRCP a promising alternative  to  diagnostic  ERCP73-77.  Moreover, 
MRCP has the following advantages over ERCP. It is noninvasive; there are no complication, 
no radiation, and no need for any contrast agent. It causes less discomfort for the patients,  
and  can  provide  useful  information  on  the  parenchymatous  organs  in  this  region  in 
combination with conventional cross-sectional MR sequences.
Patients  who undergo ERCP need sedation.  Another  disadvantage is  that  it  
affords no information on extraductal lesions, and does not opacify the obstructed segment in  
the event of total duct obstruction. It was unsuccessful in 3-10% of the cases, even in the  
largest endoscopic centers. 
When findings of chronic pancreatitis are identified in a patient without a prior  
history of chronic pancreatitis or of ethanol abuse, an obstructing lesion should be suspected. 
Pancreatic ductal adenocarcinoma is the usual cause of chronic obstructive pancreatitis and 
comprises 75% to 90% of all pancreatic carcinomas 78. Differentiating adenocarcinoma from 
mass-forming  chronic  pancreatitis  with  MR  imaging  is  sometimes  difficult.  Typically,  the 
chronically inflamed pancreas will enhance more than will pancreatic tumors on immediate 
post-gadolinium images,  particularly  those  tumors  arising  in  the  head.  Unfortunately,  the 
degree  of  enhancement  cannot  be  used  to  reliably  distinguish  these  entities  because 
abundant fibrosis is seen in both chronic pancreatitis  and carcinoma, accounting for their 
similar appearances 79.
MRCP  may  be  helpful  to  aid  in  this  differentiation,  because  chronic  alcoholic 
pancreatitis, compared with chronic obstructive pancreatitis due to adenocarcinoma, is more 
frequently associated with an irregularly dilated duct with intraductal calcification 80. The ratio 
of duct caliber to pancreatic gland width is higher in patients with carcinoma81. Also, the “duct-
penetrating sign,” seen in 85% of chronic pancreatitis and in only 4% of patients with cancer,  
helps to distinguish an inflammatory pancreatic mass from pancreatic carcinoma. The “duct-
penetrating sign” refers to a nonobstructed main pancreatic duct penetrating an inflammatory 
pancreatic mass, unlike its usual obstruction by pancreatic carcinoma.82 Furthermore, MRCP 
can  depict  the  classic  “double  duct  sign”  of  pancreatic  carcinoma  (enlargement  and 
noncommunication of the pancreatic and common bile ducts) and the imaging counterpart of  
Courvoisier's sign (an enlarged, nontender gallbladder caused by an obstructing tumor) 83. A 
normal-sized  pancreatic  duct  is  present  in  up  to  20%  of  patients  with  adenocarcinoma, 
however, and should not dissuade its diagnosis in the setting of common bile duct dilation.
These latter signs are useful when present, but MRCP (like ERCP) is thought to 
be a poor way to differentiate benign from malignant strictures. Because morphologic features 
of benign and malignant strictures overlap, ERCP may be the imaging modality of choice  
because of its ability to obtain a diagnostic sample with brush cytologic biopsy 84; however, 
MRCP,  including  MR imaging  pulse  sequences,  has  a  sensitivity  of  84% for  diagnosing 
pancreatic carcinoma, whereas the corresponding sensitivity for ERCP with brush cytology 
varies  between  33% and  85%  79 .  Adding  MRCP to  conventional  T1-weighted  and  T2-
weighted sequences improves specificity by depicting extraductal  structures not seen with 
ERCP 85. 
MRCP  has  certain  drawbacks.  Most  importantly,  it  does  not  allow  simultaneous 
therapeutic intervention. While ERCP offers a therapeutic option in the same session after the 
diagnosis is made (papillotomy, removal of choledocholithiasis, stenting of a biliary stricture,  
etc.), MRCP yields only the diagnosis. Clips, stents, pneumobilia, hemobilia and ascites might 
result  in  artifacts  and  impede  interpretation  of  the  MRCP  image.  Despite  the  new 
technological advances in MR imaging, its resolution has remained behind that of ERCP86.
The combination of conventional MR imaging with MRCP and MR angiography 
could increase the accuracy in the diagnosis, the staging of pancreatic malignancies and the  
assessment of resectability87-90. With this combined MR imaging technique, the biliary tree and 
pancreatic duct with the surrounding vessels and parenchymatous organs could be depicted 
in one examination, which makes it cost-effective.
CA 19-9:
 Several families of molecules have been studied as possible tumor markers, 
including  oncofetal  antigens  (CEA and  POA),  pancreatic  enzymes,  blood  group-related 
antigens  and,  more  recently,  oncogenes  and  tumor  suppressor  genes.  Several  studies 
indicate the value of circulating tumour marker  evaluation as a simple, sensitive, and reliable 
test facilitating the differential diagnosis between  chronic pancreatitis and cancer.91-97   Blood 
group  related  antigens,  CA  19-9  in  particular,  have  the  highest  diagnostic  efficacy  in 
distinguishing between pancreatic cancer and chronic pancreatitis. 
The sensitivity and the specificity of CA 19-9 in diagnosing pancreatic cancer 
range from 70 to 95% and 72 to 90% respectively. Although most pancreatic cancers cause 
an increase in serum CA 19-9 levels, this tumor marker does not approach 100%. This results 
from two main pathophysiological aspects: 1) since individuals with Lewis a-/b- status (7-10% 
of the general population) cannot synthesize sialyl Lewis a antigenic determinant, even if they 
have a large tumor they will have low circulating CA 19-9 levels; 2) the release of CA 19-9  
antigen in cell culture media is correlated with the number of neoplastic cells in culture, and  
this phenomenon is reflected "in vivo" by the association between CA 19-9 levels and the  
tumor stage. The clinical effect of this is that CA 19-9 has a low sensitivity in the diagnosis of  
circumscribed tumors and when used for screening programs. Regarding specificity, the lack 
of absolute results is due to several factors: 1) tumors of non-pancreatic origin may cause an 
increase  in  CA  19-9  serum  levels  (biliary:  sensitivity  55-79%;  hepatocellular  and 
cholangiocellular: sensitivity 22-51%; gastric; colorectal; ovarian; lung; breast and uterine); 2) 
benign diseases of the pancreo-biliary tree (chronic pancreatitis  and obstructive jaundice)  
may also cause significant increases in serum CA 19-9. An altered hepatic function, whether  
caused by cancer or a benign disease, may give rise to increased serum CA 19-9 levels, due  
to its reduced molecular clearance, which occurs mainly through the hepatic metabolism98.
CA 19-9 may also be useful in monitoring pancreatic cancer since it correlates 
closely  with  the  clinical  course  of  the  disease  after  surgery  and  chemotherapy  and/or  
radiotherapy. It reaches normal levels within 2 to 4 weeks after radical surgery: there is a 
transient decrease after successful palliative therapy and an increase before clinical relapse 99, 
100.
To  improve  the  effectiveness  of  serological  diagnosis  of  patients  with  pancreatic 
carcinoma, different tumour markers have been assessed, including CEA, CA 242, CA 50, 
and CA 72-4.91-94 However,  the sensitivity and specificity of these markers appeared to be 
insufficient for differentiation of pancreatic carcinoma from chronic pancreatitis. In 1996, CAM 
17-195 was described as a new useful diagnostic marker in  pancreatic carcinoma. It showed 
sensitivity similar to that of CA 19-9 but higher specificity, giving only 10% false positive  results 
in patients with chronic pancreatitis. 
Tissue polypeptide specific antigen (TPS) is a different type  of antigen that does 
not  correlate  with  tumour  mass  but  reflects tumour  proliferative  activity.101 One  study96 
revealed that elevated levels of TPS detected preoperatively 100% of patients with  pancreatic 
carcinoma.  The  introduction  of  200  U/l  as  a  decision  criterion  for  TPS level  allowed  an 
increase in the specificity of this marker to 98% and eliminated all but 2% of the false positive 
results in patients with chronic pancreatitis. Moreover, TPS is useful for detection of the early 
stages of clinical advancement of pancreatic carcinoma. 
It seems that measurement of TPS, using 200 U/l as the cut off  value, should 
facilitate more precise discrimination between the early stages of pancreatic carcinoma and 
chronic pancreatitis. 
DOUBLE DUCT SIGN:
          The double duct sign was more specifically defined as nodular, excentric, or rat-
tailed encasement of the 2 ducts.102, 103 Ralls et al.102 examined the ERCP images from 49 
patients with a stenosis of the common bile or main pancreatic duct without reference to 
clinical information. The double duct sign appeared in 4 of 8 cases of pancreatic carcinoma 
and in 15 of 41 patients with chronic pancreatitis. The investigators concluded that ERCP 
criteria alone are unreliable in differentiating pancreatitis from pancreatic cancer.
Shemesh et al.104 compared 45 patients with chronic pancreatitis alone with 10 
others who had coexisting pancreatic carcinoma. Histologic confirmation of malignant disease 
was obtained in all cases and of benign disease in 19 cases (42%) by laparotomy. All of the 
patients with cancer and 19 (42%) of those with pancreatitis were found to have a double duct 
sign. The length of the pancreatic duct stricture discriminated between benign and malignant 
disease in that all of the patients with cancer had strictures longer than 10 mm, whereas the 
length of strictures in the patients without cancer did not exceed 5 mm. The investigators 
concluded that ERCP is highly accurate in the diagnosis of pancreatic cancer even when 
there is coexisting pancreatitis. The results of this study, however, differ from those of Plumley 
et al.,105 who found in the average even longer segments of the pancreatic duct in patients 
with benign disease.
When comparing these studies, one explanation for the different results is the 
lack of a uniform definition for the term double duct sign. If the criterion is only an abnormality 
of the ducts, there will be loss of specificity, because a number of benign diseases will be 
included, for instance, chronic inflammatory changes. Restricting the definition to adjacent 
stenoses or strictures of the ducts increases the specificity
In patients with a pancreatic mass or obstructive jaundice the strictly defined double 
duct sign on ERCP yields a specificity of around 85% in predicting the presence of pancreatic 
carcinoma. Even the combination of a pancreatic mass by CT or MRI and a double duct sign 
on ERCP is no proof of pancreatic cancer.
CYTOLOGY:
In general, the ductal cells seen in chronic pancreatitis are not easily confused 
with those of pancreatic ductal adenocarcinoma. The diagnosis of primary pancreatic 
carcinoma is made by the identification of typical cytomorphologic features, including 
eccentric nuclei and vacuoles in the cytoplasm.
However, a problem arises when rare groups of cells suspicious for pancreatic 
carcinoma are found. The lack of sufficient atypical cell groups makes an unequivocal 
diagnosis of pancreatic cancer difficult (low sensitivity). The quantity of atypical cells generally 
determines whether or not a diagnosis of pancreatic cancer is superimposed on chronic 
pancreatitis. This typically results from obtaining an inadequate specimen without glandular 
tissue. Further difficulties in cytologic interpretation result from the presence of pancreatic 
intraepithelial neoplasia (PanIN) and chronic inflammatory cells. PanIN represents a 
pancreatic cancer precursor lesion commonly found in chronic pancreatitis as well as in 
“normal” tissue associated with pancreatic cancer. Cytologic sampling of PanIN in the setting 
of chronic pancreatitis can result in a false-positive diagnosis because of the presence of 
ductal atypia.
Most  cytopathologists  have  high  diagnostic  thresholds  for  the  diagnosis  of 
pancreatic ductal  adenocarcinoma. This explains the high specificity for pancreatic cancer 
diagnosis in the absence of chronic pancreatitis. The sensitivity, however, is never 100%, and 
a review of false-negative diagnoses shows most to be caused by sampling error and rarely 
because of interpretive results.106 In one study of false-positive EUS-FNAs (rate of 5%), both 
patients had a final diagnosis of chronic pancreatitis, and the reasons given for the false-
positive  results  were  inadequate  hypocellular  specimen and misinterpretation  of  enlarged 
acinar cells as malignant.107
EUS:
Linear EUS coupled with color Doppler provides real-time US imaging during 
FNA.The impact of EUS-FNA in the management of pancreatic cancer continues to expand. 
The procedure is safe, with reported complication rates being less than 1%.  108 
EUS-FNA of  the  pancreas  can  be  technically  challenging  in  patients  with 
Chronic Pancreatitis  for  two reasons: First,  EUS images alone cannot reliably detect and 
differentiate  malignant  from  inflammatory  lesions,  because  adenocarcinoma  and  focal 
pancreatitis  have a similar EUS appearance.109,  110,111 Second, even when FNA is used in 
conjunction  with  EUS,  cytologic  evaluation  of  pancreatic  tissue  in  the  setting  of  chronic 
inflammation is very difficult, because the inflammatory infiltrate may obscure or simulate a 
pancreatic malignancy.112,113 Recently, two European studies have attempted to address this 
issue.114,115 In  the  first  study,  from  Germany,  by  Brand  et  al,114 the  specificity  of  EUS to 
diagnose malignancy based on morphologic criteria was found to be as low as 53% in the 
setting of Chronic Pancreatitis. In the second study, also from Germany, by Fritsher-Ravens et 
al, 115 the sensitivity of EUS-FNA to diagnose malignancy in the setting of Chronic Pancreatitis 
was much lower when compared with patients with focal pancreatic lesions and a normal 
pancreas, 54% vs. 89%, respectively.
However, the sensitivity is much lower when compared with evaluations of other lesions 
by EUS-FNA, such as mediastinal masses (89%-96%). This decrease in sensitivity may be 
from  the  presence  of  underlying  Chronic  Pancreatitis  that  limits  imaging  and  thereby 
interpretation of pancreatic masses.110,  112,  113,  Even in patients with less advanced disease, 
difficulties  in  diagnosis  may  be  caused  by  multiple  hypoechoic  foci  in  the  pancreatic 
parenchyma that makes it difficult to decide on which area to puncture. In consequence, the  
needle may miss small-sized lesions. On the other hand, in advanced Chronic Pancreatitis, 
calcifications create an acoustic shadowing that may conceal a malignant mass.112. Several 
investigators  have  reported  cases  of  false-negative  biopsy  results  with  EUS-FNA  of 
pancreatic masses, mostly in patients with underlying Chronic Pancreatitis.  112,116, 117, 
Needle-track seeding has been a concern ever since a few cases were reported 
from use of the percutaneous route.118, 119 Lesions in the head and the uncinate process of the 
pancreas are sampled transduodenally, the duodenum usually being included in the resection 
specimen in operable patients. A potential risk is only encountered while aspirating lesions in  
the body or tail of the pancreas via the transgastric approach.
The following limitations of EUS for the detection of pancreatic tumors have been found: 
Despite the high accuracy of EUS for detection of pancreatic masses, careful 
review of published studies shows that EUS is not foolproof for detection of a pancreatic 
mass.  Pancreatic  tumors  that  were  not  visualized  by  EUS  have  been  reported  in  the 
literature.120, 121 
A pancreatic tumor may not appear as a pancreatic mass on EUS if there is  
underlying  chronic  pancreatitis  or if  the tumor has similar  echogenicity as the rest  of  the 
pancreatic parenchyma.120 
Technical factors, such as prior sphincterotomy or a stent in the biliary or pancreatic 
duct system, may create air artifacts limiting a EUS examination of the pancreatic head.
EUS by imaging  alone  is  also  unable  to  differentiate  between  a  pancreatic 
neoplasm and focal pancreatitis. EUS-guided fine-needle aspiration (FNA) helps in some of 
these cases and is discussed later.
It has long been appreciated that not only is it more difficult to identify focal masses, let 
alone malignant ones, in the setting of chronic pancreatitis, but that the specificity and the  
sensitivity of EUS-FNA in this setting is inferior.112, 122
Table 1. Sensitivity for diagnosing pancreatic cancer in the setting of focal 
chronic pancreatitis 
Sensitivity (%)
CT/MRI 77
PET 88
EUS 63-76
EUS-guided FNA 54-74
Table 2. Reasons for false EUS diagnosis of pancreatic malignancy 
The presence of a focal hypoechoic mass in the absence of diffuse evidence 
of chronic pancreatitis 
Apparent signs of vascular involvement
Apparent extension of the mass into adjacent structures
Table 3. Tips for improving the yield of pancreatic mass EUS-guided FNA in the 
setting of  chronic pancreatitis
More FNA passes; repeating the procedure
On-site cytology interpretation
Sampling of suspicious nonpancreatic lesions: lymph nodes, liver lesions
Use of EUS-core biopsy needles
Experienced pancreatic cytologist
PET:
Positron emission tomography (PET) with 18 fluoro-deoxyglucose (FDG) exploits 
increased  glucose  metabolism by malignant  tumors.  Increased glucose utilization  can  be 
demonstrated for most solid tumors, including pancreatic adenocarcinoma.123 Cell membrane 
glucose transport proteins and intracellular hexokinase levels are high in tumors, leading to 
increased uptake and phosphorylation of glucose and FDG.124, 125 The 18FDG emits positrons 
that collide with electrons, creating two gamma rays at 180-degree angles. A ring detector 
reconstructs the point of origin to generate images. The 18 FDG has proven useful in imaging 
a variety of solid tumors, for both primary tumors and metastatic disease. Primary pancreatic  
tumors also can be diagnosed with FDG-PET scanning with high sensitivity.126PET scanning 
has sensitivity similar to that of EUS for the diagnosis of local pancreatic disease. The main 
additional value of PET scanning relates to the evaluation of suspected metastatic disease. 
PET scanning clarifies CT abnormalities seen in the liver.
Imdahl et al studied 48 patients with a histologic diagnosis of pancreatic cancer, 
chronic or acute pancreatitis, and normal controls with FDG-PET. The evaluators of the PET 
scans were blinded to the patient diagnosis. An SUV cutoff of 4.0 at 1.5 hours resulted in a 
96% sensitivity and 100% specificity for pancreatic cancer, and a 100% sensitivity and 97% 
specificity for chronic pancreatitis. PET was not helpful in distinguishing acute pancreatitis 
from cancer127. The markedly different values for the reported SUV cut-off points highlight 
some of the problems that need to be resolved before this becomes a routine clinical 
procedure. In essence, the SUVs chosen in these studies were descriptive rather than 
diagnostic.
In summary, helical CT, EUS, and PET are complementary techniques in the 
evaluation of pancreatic carcinoma. CT is a standard technique that yields important data 
about local and metastatic disease. EUS is more sensitive than CT for local disease and local 
vascular invasion, which determines resectability. FNA is possible at the time of staging. PET 
scanning offers the most additional information when CT findings raise a suspicion of or are 
ambiguous for metastatic disease.
                                               AIM OF THE STUDY:
                        The aim of the study was to 
A] Prospectively analyse the mass lesion arising in the background of chronic 
pancreatitis clinically, biochemically &radiologically.
B] To identify the predictors of malignancy in patients with chronic pancreatitis without 
a tissue diagnosis.
                                           PATIENTS AND METHODS:
                  Between August 2004 to February 2007, 32 patients who presented with chronic 
pancreatitis and mass lesion to the Department of Surgical Gastroenterology, Government 
Stanley Hospital, Chennai were included for the study. Among these 10 were due to Alcoholic 
pancreatitis and 22 were due to Tropical calcific pancreatitis (TCP). Alcoholic chronic 
pancreatitis was defined as chronic pancreatitis associated with the consumption of greater 
than 50 units of alcohol per week for atleast 5 years. TCP was defined as non-alcoholic 
pancreatitis with  features  of  younger age at onset, presence of large intraductal calculi, an 
accelerated course of the disease leading to the end points  of diabetes and/or 
steatorrhoea.Detailed history was obtained from all patients.
 The variables analysed from history included 
               -Abdominal pain (duration/sudden increase)
               -Jaundice
               -Significant weight loss (Loss of >10% body weight in 6 months)
               -Persistent vomiting (due to Gastric outlet obstruction)
               -Diabetes (recent onset/ sudden worsening)
               -Steatorrhoea
               -Family history.
                              The diagnostic work up included Serum Bilirubin, CA 19-9.All patients 
underwent Ultrasonogram (USG) Abdomen and Contrast enhanced computed tomography 
(CECT) Abdomen.
                         
 In CECT the parameters that were analysed:
        A] Main pancreatic duct (MPD) size
        B] Calcification – Distribution& Type (Chunky, Stippled)
        C] Intrapancreatic cystic areas-Single/multiple
        D] Common bile duct (CBD) size
MRCP was done in selected cases. All the cases of chronic pancreatitis were confirmed by 
either histological examination or by CT features of chronic pancreatitis (eg. Calcification). All 
the mass was subjected to either intra operative biopsy or preoperative USG guided FNAC to 
rule out malignancy.
Follow up data were collected by periodic visits, telephonic interviews.
                                               Statistical analysis:
                        Simple descriptive statistics were used. Means and frequencies were 
calculated based on the numerous data points. The P values were provided to indicate 
statistical significance. Chi-square tests were used to compare categoric variables such as 
sex, and student t test was used to compare mean age, MPD size, CBD size, S.Bilirubin, CA 
19-9 between the groups. Weight loss, Bilirubin, MPD size, CBD size, CA 19-9, Presence of 
intra parenchymal cystic areas in CECT were also evaluated for predictive purposes of final 
cancer diagnosis. The sensitivity, specificity, positive predictive value (PPV), negative 
predictive value (NPV) were calculated using combination of variables with cut-offs of 6.5 g/dl 
for bilirubin, 114 U/ml for 
CA 19-9, 13.5 mm for MPD size, 16 mm for CBD size. All statistical analyses were performed 
using SAS software.
                                                         RESULTS:
                     A total of 32 patients presented with pancreatic mass in the setting of chronic 
pancreatitis. The age of the patients ranged from 19-65 years. The mean age of 
patients with malignant mass was 48.77 years whereas in inflammatory mass it was 39.47 
years.          
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Comparison of age in chronic pancreatitis with inflammatory and malignant mass
Pancreatic 
mass             N
Mean age 
(yrs) Std. Deviation Student independent t-test
Malignant 13 48.77 10.473 t= 1.95 p=0.06 
Not significant Inflammatory 19 39.47 14.785
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22 men and 10 women presented with pancreatic mass
Comparison of sex in chronic pancreatitis with inflammatory and malignant mass 
Pancreatic mass
TotalBenign Malignant
Sex Male 13 9 22
Female 6 4 10
Total 19 13 32
χ2=0.002  P=0.96   not significant
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All patients presented with abdominal pain. 3 patients with inflammatory mass and 9 
patients  with  malignant  mass  had  sudden  worsening  of  pain,  which  was  statistically 
significant.  None  of  the  patients  with  inflammatory  mass  had  gastric  outlet  obstruction 
whereas 2 patients with malignant mass had gastric outlet obstruction.10 of 19 patients with  
inflammatory mass and 12 of 13 patients with malignant mass had Diabetes mellitus (DM). 
Among these sudden worsening of DM was noted in 2 patients with inflammatory mass and 4  
patients with malignant mass. Significant weight loss was noted in 10 of 19 patients with 
inflammatory mass and 11 of 13 patients with malignant mass.  Features of Gastric outlet 
obstruction, recent onset/sudden worsening of Diabetes mellitus and significant weight loss 
were not statistically significant between the two groups.
Comparison of clinical/radiological features in chronic pancreatitis with inflammatory 
and malignant mass
 Variables
Pancreatic mass
Significance
Benign Malignant
  
N %
  
N %
Jaundice No 14 82.4% 1 10.0%            χ2=11.23
            P=0.001
      Significant
Yes
3 17.6% 9 90.0%
Abd pain 
(Sudden 
worsening)
No 16 84.2% 4 30.8%
χ2=9.41  P=0.002
Significant
Yes
3 15.8% 9 69.2%
Vomiting No 19 100.0% 11 84.6% χ2=3.12  P=0.08
Not significant
Yes   2 15.4%
Wt loss No 9 47.4% 2 15.4% χ2=3.50  P=0.06
Not significant
Yes 10 52.6% 11 84.6%
Diabetes. No 9 47.4% 2 15.4% χ2=3.50  P=0.06
Not significant
Yes 10 52.6% 11 84.6%
Smoking No 11 57.9% 6 46.2% χ2=0.43  P=0.51
Not significant
Yes 8 42.1% 7 53.8%
Intra 
pancreatic 
Cystic areas 
(CECT)
No 19 100.0% 6 46.2%
χ2=13.09 
P=0.001
Significant
Yes
  7 53.8%
Diabetes 
(Sudden 
worsening)
No 8 80.0% 6 54.5%
χ2=1.53  P=0.22
Not significant
Yes
2 20.0% 5 45.5%
Serum bilirubin:
It was analysed only in patients with head mass (i.e., 27 pts). Of 17 patients with 
inflammatory head mass serum bilirubin was elevated only in 3 patients. It ranged from 2.1 
mg% to 5.6 mg% with a mean of 3.26 mg%.In 2 of 3 patients with inflammatory head mass, 
jaundice subsided in 3 weeks whereas in none of the patients with malignant head mass 
jaundice subsided. Of 10 patients with malignant head mass serum bilirubin was elevated in 9 
patients. It ranged from 3.2 to 24.2 mg% with a mean of 10.85 mg%. From the ROC 
(Receiver operating characteristic) curve it can be noted that for an S.bilirubin value of 6.5 mg
% the sensitivity was 63.6% and the specificity was 100% in predicting malignancy. When an 
S.Bilirubin value less than 6.5 mg% was chosen the sensitivity increased but specificity 
decreased. When a bilirubin value more than 6.5 mg% was chosen the sensitivity decreased. 
Hence 6.5 mg% was used in combination with other variables to predict malignancy.
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Figure: ROC (Receiver operating characteristic) curve for predicting malignancy by 
serum bilirubin 
Test Result Variable(s): S.Bilirubin (mg%) 
Positive if 
Greater Than 
or Equal To Sensitivity
    Specificit
y
.40 1.000 1.000
.65 1.000 .941
.75 1.000 .882
.85 .909 .824
.95 .909 .647
1.05 .909 .588
1.15 .909 .471
1.35 .909 .294
1.55 .909 .235
1.70 .909 .176
1.95 .818 .176
2.65 .818 .059
4.40 .727 .059
5.90 .727 .000
6.50 .636 .000
8.20 .545 .000
9.85 .364 .000
11.85 .273 .000
14.00 .182 .000
19.30 .091 .000
25.20 .000 .000
CA 19-9:
                Since obstructive jaundice per se can elevate CA 19-9, subgroup analyses were 
done in patients with inflammatory mass.
Inflammatory mass             N CA 19-9 U/ml (mean)
Without jaundice            16    24.98
With jaundice              3     75.43
In 3 patients with equivocal findings, serial changes in CA 19-9 level were monitored .It 
identified malignancy in 2 patients in whom there was more than 3 fold rise in CA19-9 value .
Subgroup analyses were done in patients with malignant head mass
Malignant mass               N CA 19-9 U/ml (mean)
Resectable                 1    245
Locally advanced                  3    97.26
Distant metastases                  9     1170.74
CA 19-9 value of 114 U/ml was found to have a sensitivity of 61.5% and a specificity of 100% 
in predicting malignancy. Any value less than 114 U/ml had a lower specificity with a higher 
sensitivity and any value more than 114 U/ml had a lower sensitivity. Hence CA 19-9 value of 
114 U/ml was used for predicting malignancy.
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Figure: ROC curve for predicting malignancy by serum CA 19-9  
Test Result Variable(s): CA 19-9 (U/ml) 
Positive if Greater 
Than or Equal To Sensitivity       Specificity
1.330 1.000 1.000
2.665 1.000 .947
3.400 1.000 .895
3.950 .923 .895
6.100 .923 .842
8.950 .923 .789
9.900 .923 .737
10.100 .923 .684
11.100 .923 .632
13.200 .923 .579
15.200 .923 .526
18.000 .923 .474
21.850 .923 .421
25.850 .923 .368
33.000 .923 .316
40.850 .923 .263
56.000 .846 .263
73.150 .846 .211
79.000 .846 .158
83.850 .769 .105
89.985 .692 .105
98.135 .692 .053
106.000 .615 .053
114.000 .615 .000
164.000 .538 .000
354.000 .462 .000
1184.500 .308 .000
1870.000 .000 .000
MPD size:
                     It was analysed by CECT and size ranged from 3 mm to 30 mm. MPD size was 
calculated proximal to the level of obstruction (mass) .The mean value was 7.89 mm in 
patients with inflammatory mass and 14.92 mm in patients with malignant mass. MPD size of 
13.5 mm had a sensitivity if 53.8% and specificity of 100% in predicting malignancy.MPD size 
<13.5 mm had a low specificity and  MPD size >13.5 mm had a low sensitivity.Hence MPD 
size of 13.5 mm was chosen to predict malignancy.
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Figure: ROC curve for predicting malignancy by MPD size
Test Result Variable(s): MPD size (mm) 
Positive if 
Greater Than 
or Equal To Sensitivity     Specificity
2.00 1.000 1.000
4.00 1.000 .947
5.50 1.000 .789
6.50 1.000 .579
7.50 1.000 .526
8.50 .846 .421
9.50 .846 .368
10.50 .692 .211
11.50 .615 .105
13.50 .538 .000
15.50 .385 .000
17.50 .308 .000
19.50 .231 .000
25.00 .077 .000
31.00 .000 .000
CBD size:
               It was analysed only in patients with head mass. In inflammatory head mass it 
ranged from 3 to 15 mm with a mean of 9.85 mm. In malignant head mass it ranged from 15 
to 30 mm with a mean of 20.1 mm. CBD size of 16 mm had a sensitivity of 80% and a 
specificity of 100% in predicting malignancy. CBD size >16mm had a lower sensitivity and a 
value < 16 mm had a lower specificity. Hence CBD value of 16 mm was chosen to predict 
malignancy.
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Figure: ROC curve for predicting malignancy by CBD Size
Test Result Variable(s): CBD Size (mm) 
Positive if 
Greater Than or 
Equal To Sensitivity      Specificity
3.00 1.000 1.000
4.50 1.000 .706
5.50 1.000 .412
9.50 1.000 .294
13.50 1.000 .235
14.50 1.000 .118
16.00 .800 .000
17.50 .700 .000
18.50 .600 .000
19.50 .500 .000
20.50 .400 .000
23.00 .200 .000
27.50 .100 .000
31.00 .000 .000
Comparison of radiological features/Lab values in chronic pancreatitis with 
inflammatory and malignant mass
 Pancreatic 
mass N Mean
Std. 
Deviation Student independent t-test
S.Bilirubin 
(mg %)
Malignant
10 9.95 6.44 t= 4.14 p=0.002
 Benign 17 1.44 1.155
CA 19-9 
(U/ml)
Malignant
13 701.785 824.3491 t= 2.92 p=0.01
 Benign 19 32.958 34.0607
MPD size 
(mm)
Malignant
13 14.92 6.224 t= 3.83 p=0.002
 Benign 19 7.89 2.706
CBD Size 
(mm)
Malignant
10 20.10 4.60 t= 6.95 p=0.001
 Benign 17 7.53 4.50
Predicting malignancy by combination of variables:
Head mass:
Variables Sensitivity 
(%)
Specificity 
(%)
PPV
 (%)
NPV 
(%)
Bil >6.5 g%,
CA 19-9>114 U/ml
MPD>13.5mm
92 100 100 94
Bil >6.5 g%,
CA 19-9>114 U/ml
MPD>13.5mm
Multiple cystic areas (CECT)
92 100 100 94
Bil >6.5 g%,
CA 19-9>114 U/ml
MPD>13.5mm
CBD>16mm
100 100 100 100
Body and Tail mass:
Variables Sensitivity 
(%)
Specificity 
(%)
PPV
 (%)
NPV 
(%)
CA 19-9>114 U/ml
MPD>13.5mm
Multiple cystic areas 
(CECT)
85 100 100 85
                                                       DISCUSSION:
The differential diagnosis of chronic pancreatitis and pancreatic carcinoma is difficult-
clinically, surgically and even histologically. The specificity of pre operative imaging methods is 
relatively low.
The majority of pancreatic tumors (70%) are localized to the pancreatic head and 
chronic pancreatitis seems to prefer the head region as well thus causing pancreatic mass128. The 
reason being the expression of growth factor receptor c-erb B2, which belongs to the EGF receptor 
family, is positively correlated to the size of pancreatic head. In our study 89.4% of inflammatory 
mass and 76.9% of malignant mass were located in the pancreatic head. In patients with TCP, 
81.8% of malignant mass was located in the head region. This is in contrast to the study by 
H.Ramesh et al in which only 22.2 % of malignant mass was located in the pancreatic head.129
The major etiology for malignant mass in our study was TCP (84.6%) and only 15.4% of 
malignant mass were due to Alcoholic pancreatitis.
                         Frequently both chronic pancreatitis and pancreatic carcinoma present with 
the same symptoms. In either condition, most patients are thin, and even emaciated, and may 
appear to have malignant     disease.130     Augustine et al stated that weight loss and sudden 
worsening of abdominal pain to be more common with malignancy22. In our study sudden 
worsening of abdominal pain was significantly associated with malignancy whereas there was 
no difference in weight loss between the two groups.
                         80% of pancreatic cancer patients have impaired glucose metabolism131    .It 
has been proposed that amylin, a peptide with a molecular weight of 2030, or other yet 
unknown substances released from cancer cells are responsible for the impaired glucose 
tolerance. In our study there was no significant difference in recent onset/sudden worsening 
of diabetes between the two groups.
Wapnick and associates have shown that total serum bilirubin was much higher 
with pancreatic malignancy being 18.5 mg% compared with 5.6 mg% in chronic pancreatitis. 
Perhaps more important than the absolute rise of bilirubin was the pattern of elevation. In 
patients with malignancy, bilirubin rose progressively until the biliary tree was decompressed, 
while with chronic pancreatitis, bilirubin rose to an apex and then fell as the attack subsided. 
They concluded that the course of the bilirubin during the first 7-10 days of hospitalization was 
the single most accurate test distinguishing carcinoma from pancreatitis132. Frey and 
coworkers found that serum bilirubin was seldom higher than 10 mg% in chronic pancreatitis 
and usually diminished within 7-10 days as the inflammatory exacerbation subsides133.
In our study only 3 of 17 patients with inflammatory head mass (17.6%) presented with 
jaundice. Among the 3 patients jaundice subsided in 2 patients in 3 weeks.90% of patients 
with malignant head mass presented with jaundice. The mean S.bilirubin value was 3.26 g% 
in inflammatory head mass and 10.85 mg% in malignant head mass.
The usefulness of serial changes in serum CA19-9 levels in the diagnosis of 
pancreatic cancer has been emphasized by Tanaka et al134.They concluded that close follow-
up with various diagnostic modalities may be required for patients whose serum CA 19-9 
levels increase to more than two fold the initial level,because such patients are highly 
suspected of having pancreatic cancer.In our study,3 patients with equivocal findings had 
serial changes in CA 19-9 levels monitored.There was more than 3 fold rise in 2 patients 
which helped in identifying malignancy.
The “duct-penetrating sign,” seen in 85% of chronic pancreatitis and in only 4% 
of patients with cancer, helps to distinguish an inflammatory pancreatic mass from pancreatic 
carcinoma. It refers to a nonobstructed MPD penetrating an inflammatory pancreatic mass, 
unlike its usual obstruction by pancreatic carcinoma.82 Hence, gross dilatation of MPD occurs 
proximal to obstruction in malignancy. In our study gross dilatation of MPD (>13.5 mm) was 
more common with malignancy and predicted malignancy with a sensitivity of 53.8% and a 
specificity of 100%.
 Different variables were used in combination to predict malignancy without a 
tissue diagnosis.S.Bilirubin> 6.5 mg%, CA 19-9>114 U/ml, MPD>13.5 mm, CBD>16 mm was 
found to have a sensitivity, specificity, PPV&NPV of 100% in chronic pancreatitis with head 
mass. In patients with body or tail mass multiple intrapancreatic cystic lesions in CECT was 
included whereas S.Bilirubin and CBD size was excluded. CA 19-9>114 U/ml, MPD>13.5 
mm& multiple cystic lesions predicted malignancy with a specificity&PPV of 100%, sensitivity 
&NPV of 85%.
Though pancreaticoduodenectomy has been described as the procedure of 
choice in patients with chronic pancreatitis with suspected malignancy most of the evidence 
comes from the western literature where alcohol is the common etiology. In the Indian 
scenario, Where TCP is very common pancreaticoduodenectomy is associated with 
considerable postoperative morbidity because TCP patients do nutrionally very poor with 
frequent hospitalization following pancreaticoduodenectomy. Hence preoperative diagnosis of 
malignancy has to be made with certainity. In this setting our model for predicting malignancy 
may be of considerable value.
                                                         Strength of the study:
a) Ability to suggest predictive factors to aid in the differentiation of benign and 
malignant disease without a tissue diagnosis.
b) The variables like S.Bilirubin, MPD size, CBD size, multiple intrapancreatic cystic 
lesions are unlikely to be influenced by the presence of metastases. Hence it is 
applicable to patients with operable tumors.
c) No study has been reported in the international literature of predicting malignancy 
in chronic pancreatitis with mass lesion using a combination of variables.
The limitation of the study is the small sample size.
                                               FUTURE DEVELOPMENTS:
                        The genes most frequently found to be altered in patients with pancreatic 
adenocarcinoma are K-ras, p53, p16 and they are deleted in pancreatic carcinoma-locus 4 
(DPC4).
                         More than 90% of pancreatic tumors bear codon 12 K-ras point mutations. 
This is the highest frequency to be reported for any tumor type. Such mutations have been 
observed in the early phases of pancreatic carcinogenesis, determining the synthesis of an 
altered p21 protein. Normal p21 shifts from an active (bound to GTP) to an inactive (bound to 
GDP) state via its intrinsic GTPase activity and via its sensitivity to the activity of GTPase 
activating protein (GAP). The transformed p21 becomes insensitive to GAP, thus leading this 
protein to a constitutive and permanent activation stimulating cell growth. Another gene 
frequently altered in pancreatic cancer is p16 (homozygously deleted in about 40% of 
pancreatic carcinomas), an inhibitor of cyclin-dependent kinase 4 (CDK4) that promotes the 
progression of the cell division cycle through the late G1 phase to G1/S 135.  The genetic 
alterations involving p16 may be the methylation of the promoter region (15% of cases), 
homozygous deletion (40%) or deletion accompanied by intragenic mutations in the other 
allele (40%). The tumor suppressor gene p53, which controls the cell cycle and induces 
apoptosis, is altered in 50 to 70% of different types of pancreatic cancer, and is usually 
inactivated by the loss of one allele accompanied by a intragenic mutation of the other allele 
135, 136. The gene DPC4 is altered in about 50% of pancreatic tumors, and encodes a protein 
belonging to the SMAD family, which is involved in the nuclear translocation of the inhibitory 
signal for cell growth starting from the interaction between transforming growth factor (TGF) 
beta1 and its membrane receptor, TGF-beta1R 135, 137, 138.
The above-mentioned genes have been studied in tissue samples and some, K-
ras in particular, have also been evaluated in biological samples (not only pancreatic tissue) in 
order to enable the identification, in easily obtained samples, of gene alterations indicating the 
presence of a pancreatic tumor. K-ras point mutations have been studied in duodenal juice, in 
stools and in serum samples 139, 140, 141. Overall, its sensitivity in the detection of pancreatic 
tumors decreases when a search is made for K-ras in samples other than from the tumor 
tissue.
The detection of pancreatic cancer: sensitivity and overall specificity of K-ras point mutation 
identification in different samples.
 Sensitivity Specificity
Tumor tissue 71-100%  
Duodenal juice 25-100%  
Stool 55%  
Serum 0-60%  
Overall  66-100%
                 In laboratory medicine, serum and/or stools should be satisfactory for use as 
samples for diagnostic purposes, since they are easily obtained, thus favouring patient 
compliance. However, the sensitivity of K-ras point mutation identification is unsatisfactory in 
diagnosing pancreatic cancer using these samples, perhaps partly due to methodological 
problems (presence of Taq polymerase inhibitors in faecal samples and low amounts of 
mutated K-ras in a wide background of normal serum K-ras). It cannot therefore as yet be 
used in clinical practice, although it may be routinely used in the future, in line with 
improvements in molecular biology techniques.
                                                          CONCLUSION:
In the appropriate clinical setting, a patient with sudden worsening of abdominal 
pain with S.Bilirubin > 6.5 mg%, CA 19-9>114 U/ml, MPD>13.5 mm, CBD>16 mm& multiple 
Intrapancreatic cystic lesions should be strongly considered to have malignancy. 
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                                                     Abbreviations :-
1. TCP : Tropical Calcific Pancreatitis
2. USG : Ultrasound
3. CECT : Contrast Enhanced Computed Tomography
4. MRCP : Magnetic Resonance Cholangio Pancreatography
5. ERCP : Endoscopic Retrograde Cholangio Pancreatography
6. EUS : Endo Ultrasound
7. EUS -  FNA : Endo Ultrasound guided Fine Needle Aspiration
8. PET : Positron Emission Tomography
9. MPD : Main Pancreatic duct
10.CBD : Common Bile Duct
11. PPV : Positive Predictive Value
12.NPV : Negative Predictive Value
13.ROC : Receiver Operating Charecteristic
14.SPINK : Serine Protease Inhibitor,Kazal type 1
15.PTC : Percutaneous Transhepatic Cholangiography
16.FDG : Fluoro – deoxy glucose. 
